AtriCure is a medical device company providing innovative solutions for the treatment of atrial fibrillation (Afib). Afib affects more than 33 million people worldwide and is a serious cardiac condition which increases the risk of stroke, slows down blood flow, and can lead to other serious heart conditions. AtriCure has the first and only surgical device approved to treat Afib in the U.S. In addition, we pioneered the AtriClip®, a left atrial appendage (LAA) occlusion device that is the most widely implanted device for LAA management, and in August of 2019 we acquired SentreHEART, a privately held developer of percutaneous left atrial appendage management solutions. We also market a device for intrathoracic pain management. Through our commitment to product innovation, and education grounded in clinical science, we're working to reduce the global Afib epidemic, and we do this by living out our core values: Patients, People, and Partners.
Employees come together regularly to share ideas and collaborate on projects.
The company headquarters in Mason is home to the largest number of AtriCure employees, but the company has a global reach.
AtriCure's Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib.
AtriCure supports its humble culture through various programs and activities, including paid time off for volunteering and active involvement in causes such as the American Heart Association's Heart Mini, Adopt-A-Class, and mission outreach.